CAR T-cell therapy is a revolutionary method of cancer therapy employing a patient's own immune cells to attack and kill cancer. The session "CAR T Therapy" emphasizes the science, clinical uses, and developments of this new therapy, which has recorded remarkable successes in some blood cancers.
This treatment entails harvesting a patient's T-cells and genetically modifying them to create chimeric antigen receptors (CARs) that can target and kill cancer cells. After engineering, the CAR T-cells are amplified in the laboratory and given back to the patient's body, where they target and kill tumor cells. This targeted therapy has shown promising response rates for diseases like leukemia and lymphoma, especially in patients who have been unresponsive to traditional therapies.
The session also discusses challenges and solutions for advancing CAR T-cell therapy, such as the control of adverse effects such as cytokine release syndrome and neurotoxicity, increasing durability of response, and broadening to solid tumors. Investigators are examining combination treatments and second-generation CAR designs to enhance safety and efficacy.
Participants will learn how CAR T-cell therapy is transforming oncology, the state of clinical success today, and research driving the future of personalized immunotherapy. This session offers an overall understanding of CAR T-cell approaches and how they have the potential to revolutionize cancer care.
Welcome to the Cancer and Oncology Conference 2026, where global researchers, clinicians, and academics meet to share advances in cancer biology, precision medicine, diagnostics, therapies, and global solutions for patient care.
